$NVRO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEVRO CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NEVRO CORP. Get notifications about new insider transactions in NEVRO CORP for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 24 2021 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 179.03 | 6,445 | 1,153,837 | 231,277 | 237.7 K to 231.3 K (-2.71 %) |
| Jun 22 2021 | NVRO | NEVRO CORP | GROSSMAN D KEITH | Chairman, President ... | Payment of Exercise | F | 160.45 | 4,874 | 782,033 | 118,838 | 123.7 K to 118.8 K (-3.94 %) |
| Jun 16 2021 | NVRO | NEVRO CORP | MacLeod Roderick H. | Chief Financial Off ... | Payment of Exercise | F | 158.49 | 1,583 | 250,890 | 19,081 | 20.7 K to 19.1 K (-7.66 %) |
| May 26 2021 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 1,167 | 0 | 8,198 | 7 K to 8.2 K (+16.60 %) |
| May 26 2021 | NVRO | NEVRO CORP | OBOYLE KEVIN C | Director | Grant | A | 0.00 | 1,167 | 0 | 10,918 | 9.8 K to 10.9 K (+11.97 %) |
| May 26 2021 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 1,167 | 0 | 18,039 | 16.9 K to 18 K (+6.92 %) |
| May 26 2021 | NVRO | NEVRO CORP | McCormick Shawn | Director | Grant | A | 0.00 | 1,167 | 0 | 8,457 | 7.3 K to 8.5 K (+16.01 %) |
| May 26 2021 | NVRO | NEVRO CORP | McCormick Shawn | Director | Sell | S | 149.65 | 482 | 72,131 | 7,290 | 7.8 K to 7.3 K (-6.20 %) |
| Apr 02 2021 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 120 | 0 | 39,651 | 39.5 K to 39.7 K (+0.30 %) |
| Apr 02 2021 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 188 | 0 | 236,555 | 236.4 K to 236.6 K (+0.08 %) |
| Apr 02 2021 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 147 | 0 | 16,872 | 16.7 K to 16.9 K (+0.88 %) |
| Apr 02 2021 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 147 | 0 | 16,872 | 16.7 K to 16.9 K (+0.88 %) |
| Mar 23 2021 | NVRO | NEVRO CORP | GROSSMAN D KEITH | Chairman, President ... | Payment of Exercise | F | 142.81 | 4,873 | 695,913 | 127,975 | 132.8 K to 128 K (-3.67 %) |
| Mar 15 2021 | NVRO | NEVRO CORP | GROSSMAN D KEITH | Chairman, President ... | Grant | A | 0.00 | 20,953 | 0 | 132,848 | 111.9 K to 132.8 K (+18.73 %) |
| Mar 12 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 65,575 | |
| Mar 12 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 148.08 | 750 | 111,060 | 39,218 | 40 K to 39.2 K (-1.88 %) |
| Mar 12 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 39,968 | 39.2 K to 40 K (+1.91 %) |
| Mar 04 2021 | NVRO | NEVRO CORP | MacLeod Roderick H. | Chief Financial Off ... | Grant | A | 0.00 | 8,612 | 0 | 20,664 | 12.1 K to 20.7 K (+71.46 %) |
| Mar 04 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Payment of Exercise | F | 168.11 | 706 | 118,686 | 39,218 | 39.9 K to 39.2 K (-1.77 %) |
| Mar 04 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Grant | A | 0.00 | 9,596 | 0 | 39,924 | 30.3 K to 39.9 K (+31.64 %) |
| Mar 04 2021 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 168.11 | 640 | 107,590 | 34,979 | 35.6 K to 35 K (-1.80 %) |
| Mar 04 2021 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Grant | A | 0.00 | 7,136 | 0 | 35,619 | 28.5 K to 35.6 K (+25.05 %) |
| Mar 03 2021 | NVRO | NEVRO CORP | Vale Brad | Director | Sell | S | 169.08 | 1,510 | 255,317 | 7,031 | 8.5 K to 7 K (-17.68 %) |
| Mar 03 2021 | NVRO | NEVRO CORP | Vale Brad | Director | Sell | S | 168.32 | 1,278 | 215,108 | 8,541 | 9.8 K to 8.5 K (-13.02 %) |
| Mar 03 2021 | NVRO | NEVRO CORP | Vale Brad | Director | Sell | S | 167.04 | 2,012 | 336,090 | 9,819 | 11.8 K to 9.8 K (-17.01 %) |
| Mar 03 2021 | NVRO | NEVRO CORP | Vale Brad | Director | Sell | S | 166.05 | 503 | 83,524 | 11,831 | 12.3 K to 11.8 K (-4.08 %) |
| Feb 12 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 66,325 | |
| Feb 12 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 182.55 | 750 | 136,913 | 30,328 | 31.1 K to 30.3 K (-2.41 %) |
| Feb 12 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 31,078 | 30.3 K to 31.1 K (+2.47 %) |
| Jan 13 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 67,075 | |
| Jan 13 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 169.80 | 750 | 127,350 | 30,328 | 31.1 K to 30.3 K (-2.41 %) |
| Jan 13 2021 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 31,078 | 30.3 K to 31.1 K (+2.47 %) |
| Jan 05 2021 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 173.10 | 1,365 | 236,282 | 28,483 | 29.8 K to 28.5 K (-4.57 %) |
| Jan 05 2021 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 96 | 0 | 39,531 | 39.4 K to 39.5 K (+0.24 %) |
| Dec 22 2020 | NVRO | NEVRO CORP | GROSSMAN D KEITH | Chairman, President ... | Payment of Exercise | F | 181.23 | 4,998 | 905,788 | 111,895 | 116.9 K to 111.9 K (-4.28 %) |
| Dec 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 67,825 | |
| Dec 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 160.72 | 450 | 72,322 | 30,328 | 30.8 K to 30.3 K (-1.46 %) |
| Dec 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 161.96 | 300 | 48,588 | 30,778 | 31.1 K to 30.8 K (-0.97 %) |
| Dec 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 31,078 | 30.3 K to 31.1 K (+2.47 %) |
| Dec 04 2020 | NVRO | NEVRO CORP | SIEGEL SUSAN E | Director | Grant | A | 0.00 | 1,883 | 0 | 1,883 | 0 to 1.9 K |
| Nov 12 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 68,575 | |
| Nov 12 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 170.75 | 750 | 128,063 | 30,328 | 31.1 K to 30.3 K (-2.41 %) |
| Nov 12 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 31,078 | 30.3 K to 31.1 K (+2.47 %) |
| Nov 03 2020 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 149.21 | 2,192 | 327,068 | 29,848 | 32 K to 29.8 K (-6.84 %) |
| Oct 26 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 165.00 | 1,817 | 299,805 | 30,328 | 32.1 K to 30.3 K (-5.65 %) |
| Oct 21 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 155.00 | 1,000 | 155,000 | 32,145 | 33.1 K to 32.1 K (-3.02 %) |
| Oct 13 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 69,325 | |
| Oct 13 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 151.47 | 750 | 113,603 | 33,145 | 33.9 K to 33.1 K (-2.21 %) |
| Oct 13 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 33,895 | 33.1 K to 33.9 K (+2.26 %) |
| Oct 13 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 150.00 | 1,000 | 150,000 | 33,145 | 34.1 K to 33.1 K (-2.93 %) |
| Oct 13 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 151.62 | 200 | 30,324 | 236,207 | 236.4 K to 236.2 K (-0.08 %) |
| Oct 13 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 151.09 | 703 | 106,219 | 236,407 | 237.1 K to 236.4 K (-0.30 %) |
| Oct 13 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 150.31 | 20,529 | 3,085,745 | 237,110 | 257.6 K to 237.1 K (-7.97 %) |
| Oct 02 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 199 | 0 | 257,639 | 257.4 K to 257.6 K (+0.08 %) |
| Oct 02 2020 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 120 | 0 | 39,435 | 39.3 K to 39.4 K (+0.31 %) |
| Oct 02 2020 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 113 | 0 | 12,244 | 12.1 K to 12.2 K (+0.93 %) |
| Oct 02 2020 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 113 | 0 | 12,244 | 12.1 K to 12.2 K (+0.93 %) |
| Oct 02 2020 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 123 | 0 | 16,626 | 16.5 K to 16.6 K (+0.75 %) |
| Oct 02 2020 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 123 | 0 | 16,626 | 16.5 K to 16.6 K (+0.75 %) |
| Sep 22 2020 | NVRO | NEVRO CORP | GROSSMAN D KEITH | Chairman, President ... | Payment of Exercise | F | 142.50 | 4,998 | 712,215 | 116,893 | 121.9 K to 116.9 K (-4.10 %) |
| Sep 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 148.19 | 880 | 130,411 | 257,440 | 258.3 K to 257.4 K (-0.34 %) |
| Sep 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 147.41 | 4,169 | 614,564 | 258,320 | 262.5 K to 258.3 K (-1.59 %) |
| Sep 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 146.59 | 5,977 | 876,139 | 262,489 | 268.5 K to 262.5 K (-2.23 %) |
| Sep 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 145.53 | 5,002 | 727,928 | 268,466 | 273.5 K to 268.5 K (-1.83 %) |
| Sep 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 145.27 | 2,000 | 290,546 | 273,468 | 275.5 K to 273.5 K (-0.73 %) |
| Sep 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 70,075 | |
| Sep 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 139.14 | 750 | 104,355 | 34,145 | 34.9 K to 34.1 K (-2.15 %) |
| Sep 14 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 34,895 | 34.1 K to 34.9 K (+2.20 %) |
| Sep 04 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 145.25 | 3,400 | 493,864 | 275,468 | 278.9 K to 275.5 K (-1.22 %) |
| Aug 31 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 141.34 | 10,819 | 1,529,196 | 278,868 | 289.7 K to 278.9 K (-3.73 %) |
| Aug 31 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 140.55 | 8,081 | 1,135,807 | 289,687 | 297.8 K to 289.7 K (-2.71 %) |
| Aug 31 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 141.34 | 10,819 | 1,529,196 | 278,868 | 289.7 K to 278.9 K (-3.73 %) |
| Aug 31 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 140.55 | 8,081 | 1,135,807 | 289,687 | 297.8 K to 289.7 K (-2.71 %) |
| Aug 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 140.05 | 300 | 42,016 | 347,768 | 348.1 K to 347.8 K (-0.09 %) |
| Aug 17 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 140.05 | 300 | 42,016 | 347,768 | 348.1 K to 347.8 K (-0.09 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 138.70 | 400 | 55,479 | 38,054 | 38.5 K to 38.1 K (-1.04 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 136.37 | 1,000 | 136,373 | 38,454 | 39.5 K to 38.5 K (-2.53 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 135.64 | 1,474 | 199,937 | 39,454 | 40.9 K to 39.5 K (-3.60 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 134.42 | 1,626 | 218,563 | 40,928 | 42.6 K to 40.9 K (-3.82 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 140.11 | 2,828 | 396,231 | 348,068 | 350.9 K to 348.1 K (-0.81 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 138.88 | 2,337 | 324,550 | 350,896 | 353.2 K to 350.9 K (-0.66 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 138.44 | 3,813 | 527,868 | 353,233 | 357 K to 353.2 K (-1.07 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 136.18 | 24,208 | 3,296,735 | 357,046 | 381.3 K to 357 K (-6.35 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 135.58 | 19,785 | 2,682,500 | 381,254 | 401 K to 381.3 K (-4.93 %) |
| Aug 12 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 134.34 | 30,469 | 4,093,257 | 401,039 | 431.5 K to 401 K (-7.06 %) |
| Aug 10 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | M | 64.95 | 750 | 48,713 | 70,825 | |
| Aug 10 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Sell | S | 140.11 | 750 | 105,083 | 34,145 | 34.9 K to 34.1 K (-2.15 %) |
| Aug 10 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Buy | M | 64.95 | 750 | 48,713 | 34,895 | 34.1 K to 34.9 K (+2.20 %) |
| Aug 10 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Payment of Exercise | F | 141.77 | 4,476 | 634,563 | 34,145 | 38.6 K to 34.1 K (-11.59 %) |
| Jul 02 2020 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 72 | 0 | 16,503 | 16.4 K to 16.5 K (+0.44 %) |
| Jul 02 2020 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 65 | 0 | 12,131 | 12.1 K to 12.1 K (+0.54 %) |
| Jul 02 2020 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 70 | 0 | 39,315 | 39.2 K to 39.3 K (+0.18 %) |
| Jul 02 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 116 | 0 | 431,508 | 431.4 K to 431.5 K (+0.03 %) |
| Jun 23 2020 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Payment of Exercise | F | 127.64 | 4,998 | 637,945 | 121,891 | 126.9 K to 121.9 K (-3.94 %) |
| Jun 17 2020 | NVRO | NEVRO CORP | MacLeod Roderick H. | Chief Financial Off ... | Grant | A | 0.00 | 12,052 | 0 | 12,052 | 0 to 12.1 K |
| Jun 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 121.53 | 2,311 | 280,856 | 59,179 | 61.5 K to 59.2 K (-3.76 %) |
| Jun 08 2020 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 121.53 | 462 | 56,147 | 32,040 | 32.5 K to 32 K (-1.42 %) |
| May 26 2020 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 1,376 | 0 | 12,066 | 10.7 K to 12.1 K (+12.87 %) |
| May 26 2020 | NVRO | NEVRO CORP | OBOYLE KEVIN C | Director | Grant | A | 0.00 | 1,376 | 0 | 9,751 | 8.4 K to 9.8 K (+16.43 %) |
| May 26 2020 | NVRO | NEVRO CORP | McCormick Shawn | Director | Sell | S | 126.50 | 1,020 | 129,030 | 7,772 | 8.8 K to 7.8 K (-11.60 %) |
| May 26 2020 | NVRO | NEVRO CORP | McCormick Shawn | Director | Grant | A | 0.00 | 1,376 | 0 | 8,792 | 7.4 K to 8.8 K (+18.55 %) |
| May 26 2020 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Grant | A | 0.00 | 1,376 | 0 | 9,592 | 8.2 K to 9.6 K (+16.75 %) |
| May 26 2020 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 1,376 | 0 | 39,245 | 37.9 K to 39.2 K (+3.63 %) |
| May 26 2020 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 1,376 | 0 | 431,392 | 430 K to 431.4 K (+0.32 %) |
| May 26 2020 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 1,376 | 0 | 16,431 | 15.1 K to 16.4 K (+9.14 %) |
| Apr 14 2020 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Grant | A | 0.00 | 32,392 | 0 | 126,889 | 94.5 K to 126.9 K (+34.28 %) |
| Apr 02 2020 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 157 | 0 | 10,690 | 10.5 K to 10.7 K (+1.49 %) |
| Apr 02 2020 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 172 | 0 | 15,055 | 14.9 K to 15.1 K (+1.16 %) |
| Apr 02 2020 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 167 | 0 | 37,869 | 37.7 K to 37.9 K (+0.44 %) |
| Mar 20 2020 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Payment of Exercise | F | 80.30 | 4,994 | 401,018 | 94,497 | 99.5 K to 94.5 K (-5.02 %) |
| Mar 04 2020 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Grant | A | 0.00 | 4,993 | 0 | 32,264 | 27.3 K to 32.3 K (+18.31 %) |
| Mar 04 2020 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Grant | A | 0.00 | 5,446 | 0 | 38,621 | 33.2 K to 38.6 K (+16.42 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 42.30 | 5,156 | 218,099 | 11,344 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 42.30 | 5,156 | 218,099 | 11,344 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 76.81 | 7,312 | 561,635 | 5,688 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 76.81 | 7,312 | 561,635 | 5,688 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 87.62 | 10,833 | 949,187 | 2,500 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 87.62 | 10,833 | 949,187 | 2,500 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 57.89 | 19,583 | 1,133,660 | 417 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | M | 57.89 | 19,583 | 1,133,660 | 417 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 130.83 | 600 | 78,495 | 18,658 | 19.3 K to 18.7 K (-3.12 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 130.83 | 600 | 78,495 | 18,658 | 19.3 K to 18.7 K (-3.12 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 130.13 | 10,313 | 1,342,058 | 19,258 | 29.6 K to 19.3 K (-34.88 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 130.13 | 10,313 | 1,342,058 | 19,258 | 29.6 K to 19.3 K (-34.88 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 129.34 | 17,205 | 2,225,262 | 29,571 | 46.8 K to 29.6 K (-36.78 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 129.34 | 17,205 | 2,225,262 | 29,571 | 46.8 K to 29.6 K (-36.78 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 128.25 | 2,758 | 353,722 | 46,776 | 49.5 K to 46.8 K (-5.57 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 128.25 | 2,758 | 353,722 | 46,776 | 49.5 K to 46.8 K (-5.57 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 127.06 | 7,404 | 940,773 | 49,534 | 56.9 K to 49.5 K (-13.00 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 127.06 | 7,404 | 940,773 | 49,534 | 56.9 K to 49.5 K (-13.00 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 126.47 | 4,604 | 582,265 | 56,938 | 61.5 K to 56.9 K (-7.48 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Sell | S | 126.47 | 4,604 | 582,265 | 56,938 | 61.5 K to 56.9 K (-7.48 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 42.30 | 5,156 | 218,099 | 61,542 | 56.4 K to 61.5 K (+9.14 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 42.30 | 5,156 | 218,099 | 61,542 | 56.4 K to 61.5 K (+9.14 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 76.81 | 7,312 | 561,635 | 56,386 | 49.1 K to 56.4 K (+14.90 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 76.81 | 7,312 | 561,635 | 56,386 | 49.1 K to 56.4 K (+14.90 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 87.62 | 10,833 | 949,187 | 49,074 | 38.2 K to 49.1 K (+28.33 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 87.62 | 10,833 | 949,187 | 49,074 | 38.2 K to 49.1 K (+28.33 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 57.89 | 19,583 | 1,133,660 | 38,241 | 18.7 K to 38.2 K (+104.96 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Buy | M | 57.89 | 19,583 | 1,133,660 | 38,241 | 18.7 K to 38.2 K (+104.96 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 8,000 | 28,800 | 33,394 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 8,000 | 28,800 | 33,394 | |
| Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 8,000 | 28,800 | 61,490 | 53.5 K to 61.5 K (+14.96 %) |
| Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 8,000 | 28,800 | 61,490 | 53.5 K to 61.5 K (+14.96 %) |
| Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 17,718 | 1,120,309 | 0 | |
| Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 120.11 | 17,718 | 2,128,086 | 53,490 | 71.2 K to 53.5 K (-24.88 %) |
| Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 17,718 | 1,120,309 | 71,208 | 53.5 K to 71.2 K (+33.12 %) |
| Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 17,718 | 1,120,309 | 0 | |
| Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 120.11 | 17,718 | 2,128,086 | 53,490 | 71.2 K to 53.5 K (-24.88 %) |
| Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 17,718 | 1,120,309 | 71,208 | 53.5 K to 71.2 K (+33.12 %) |